Log in

Relevant bibliographies by topics / Fungi Aspergillus / Books

To see the other types of publications on this topic, follow the link: Fungi Aspergillus.

Books on the topic 'Fungi Aspergillus'

Author: Grafiati

Published: 4 June 2021

Last updated: 2 February 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 18 books for your research on the topic 'Fungi Aspergillus.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse books on a wide variety of disciplines and organise your bibliography correctly.

1

International Penicillium and Aspergillus Workshop (1st 1985 Trippenhuis of the Royal Dutch Academy of Sciences and letters). Advances in penicillium and aspergillus systematics. New York: Plenum Press, 1985.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

2

Hore, William P. Genetic manipulation of the filamentous fungus Aspergillus Terreus. Dublin: University College Dublin, 1997.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

3

Ichishima, Eiji. Unique enzymes of Aspergillus fungi used in Japanese bioindustries. Hauppauge, N.Y: Nova Science Publishers, 2011.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

4

Trojanowska, Krystyna. Grzyby z rodzaju Aspergillus i Penicillium jako wskaźnik oceny jakości ziarna zbóż. Poznań: Wydawn. Akademii Rolniczej w Poznaniu, 1988.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

5

Moorehead, David James. Studies on the saccharification of starch by filamentous fungi of the genus Aspergillus in various fermentation systems. [s.l: The Author], 1989.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

6

Smith, J. E. Aspergillus. Springer, 2012.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

7

E, Smith John, ed. Aspergillus. New York: Plenum Press, 1994.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

8

Samson, Robert. Advances in Penicillium and Aspergillus Systematics: ). Springer, 2011.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

9

Samson, Robert. Advances in Penicillium and Aspergillus Systematics. Springer, 1986.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

10

Garrad, Richard C. Lysine biosynthesis in Aspergillus fumigatus, Filobasidiella neoformans and Candida albicans. 1989.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

11

Drake, Sarah, and Jonathan Sandoe. Fungal cardiovascular infections. Edited by Christopher C. Kibbler, Richard Barton, Neil A. R. Gow, Susan Howell, Donna M. MacCallum, and Rohini J. Manuel. Oxford University Press, 2017. http://dx.doi.org/10.1093/med/9780198755388.003.0021.

Full text

Abstract:

Fungal cardiovascular disease can broadly be divided into four groups: infective endocarditis (including implantable cardiac electronic devices), mycotic aneurysms, vascular graft infections, and intravascular catheter-related infections. These conditions are rare but are associated with significant morbidity and mortality, which may be in excess of 80% in certain groups of patients. Candida spp. and Aspergillus spp. account for the majority of these infections, but rare fungi may also be involved, particularly in infective endocarditis, where they are responsible for approximately 25% of cases. This chapter will cover the epidemiology, causative fungi, clinical features, diagnosis, management, and prevention of these four fungal cardiovascular conditions.

APA, Harvard, Vancouver, ISO, and other styles

12

Tunnicliffe, Georgia, and Matthew Wise. Pulmonary fungal infections. Oxford University Press, 2017. http://dx.doi.org/10.1093/med/9780199657742.003.0007.

Full text

Abstract:

Pulmonary fungal infections remain relatively uncommon, although they are increasingly diagnosed as a consequence of a growing population of immunocompromised individuals, foreign travel, and improved diagnostic tools. Groups who were not previously thought to be at significant risk of invasive disease are also being recognized. The increasing incidence of fungal lung disease as a consequence of changing patient demographics means that clinicians will encounter cases in outpatient clinics, medical admission departments, and the intensive care unit with increasing frequency. As international travel increases, so too will presentations of endemic mycoses to respiratory physicians practising in the United Kingdom. Many fungi, such as Aspergillus species, are ubiquitous and can cause a spectrum of pulmonary disorders from colonization, leading to hypersensitivity reactions, to invasive disease with high mortality rates. This chapter considers commonly encountered fungi and how diseases associated with them may present.

APA, Harvard, Vancouver, ISO, and other styles

13

Lester, Rebecca, and John Rex. Fungaemia and disseminated infection. Edited by Christopher C. Kibbler, Richard Barton, Neil A. R. Gow, Susan Howell, Donna M. MacCallum, and Rohini J. Manuel. Oxford University Press, 2017. http://dx.doi.org/10.1093/med/9780198755388.003.0025.

Full text

Abstract:

Invasive fungal disease can present without localization or obvious target organ involvement. These disseminated mycoses occur predominantly in patients who are immunocompromised, particularly from haematological malignancy and HIV. Candidiasis and aspergillosis are the commonest forms of disseminated fungal infection worldwide, but an increasing number of non-Candida yeasts and non-Aspergillus moulds have emerged as important causes of invasive disease in recent years. Endemic fungi such as Histoplasma capsulatum are important causes of invasive disease within limited geographic regions. Fever is the commonest manifestation of disseminated fungal infection, but other clinical features such as cutaneous manifestations may point to a specific diagnosis. Definitive diagnosis relies on the detection of fungi in tissue or blood, but serological tests can augment diagnosis in some infections. Mortality from disseminated fungal disease is high and prompt initiation of antifungal therapy—where invasive disease is suspected—is essential.

APA, Harvard, Vancouver, ISO, and other styles

14

Clark, Heather L., and Eric Pearlman. Fungal eye infections. Edited by Christopher C. Kibbler, Richard Barton, Neil A. R. Gow, Susan Howell, Donna M. MacCallum, and Rohini J. Manuel. Oxford University Press, 2017. http://dx.doi.org/10.1093/med/9780198755388.003.0028.

Full text

Abstract:

Mycotic keratitis is a fungal infection of the cornea that leads to severe, painful ulceration and loss of vision, and is a major cause of blindness worldwide, particularly in the developing world. Major risk factors for mycotic keratitis include ocular trauma and contact lens use. Both yeasts and moulds can cause mycotic keratitis, with the filamentous moulds of the Fusarium and Aspergillus genera the most common aetiological agents worldwide. Fungi, particularly Candida spp. yeasts, can also cause endophthalmitis—a painful, blinding infection of the posterior eye. Treatment of these infections is challenging owing to a limited arsenal of antifungal agents and highly variable susceptibility among causative fungi. Furthermore, associated inflammation contributes greatly to tissue damage and permanent blindness. Studies using experimental models of mycotic keratitis have revealed new targets for novel antifungal agents and anti-inflammatory therapies that have the potential to reduce the impact of these devastating infections.

APA, Harvard, Vancouver, ISO, and other styles

15

Todd, Stacy, and Nick Beeching. Fungal infection. Edited by Patrick Davey and David Sprigings. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780199568741.003.0315.

Full text

Abstract:

Fungi, comprising yeasts, moulds, and higher fungi, have a worldwide distribution and are uncommon causes of disease in healthy individuals. However, over the last 20 years, invasive fungal disease (IFD) has become an increasing cause of morbidity and mortality. This is probably due to the increasing numbers of patients with underlying host conditions, which predispose to opportunistic IFD (e.g. transplant and anti-tumour necrosis factor immunosuppression, HIV, or chronic lung disease), and to increased recognition of endemic IFD (e.g. histoplasmosis), which cause disease in both immunocompetent and immunocompromised hosts in selected geographic locations. Diagnosis of IFD remains a challenge. Symptoms are often non-specific, and a definite diagnosis requires invasive sampling with appropriate laboratory testing of these samples. Non-invasive tests are being developed, but their positive and negative predictive values still need validation. Diagnostic criteria (‘proven, probable, and possible’) established primarily for use in research and clinical trials can also prove useful in clinical environments. However, the most important step in identifying patients with IFD is to consider the diagnosis in those at risk. This chapter will focus on the commonest causes of IFD (Candida spp., Aspergillus spp., Cryptococcus spp., and histoplasmosis).

APA, Harvard, Vancouver, ISO, and other styles

16

Mack, Damien, Simon Warren, Shara Palanivel, and Christopher P. Conlon. Fungal bone and joint infections. Edited by Christopher C. Kibbler, Richard Barton, Neil A. R. Gow, Susan Howell, Donna M. MacCallum, and Rohini J. Manuel. Oxford University Press, 2017. http://dx.doi.org/10.1093/med/9780198755388.003.0020.

Full text

Abstract:

Although fungal infections of bones and joints are rare, the increasing incidence of invasive fungal disease, along with an increased population of immunosuppressed patients and individuals with multiple comorbidities, means that these infections are also increasing. The most common organisms are Candida and Aspergillus species, although the endemic dimorphic fungi are responsible for significant numbers of cases in some parts of the world. Most infections occur following haematogenous spread, but invasion from contiguous infection occurs, as does direct inoculation after trauma or surgery. Clinical presentations differ somewhat between children and adults, with the latter more likely to have vertebral osteomyelitis. Clinical presentations may be subtle, often without fever or raised inflammatory markers, and diagnosis may be delayed as a consequence. Diagnosis rests on clinical suspicion coupled with the need to obtain tissue for culture and for histology. Appropriate antifungal therapy usually needs to be prolonged and combined with surgical debridement.

APA, Harvard, Vancouver, ISO, and other styles

17

Bicanic, Tihana, and Thomas S. Harrison. Fungal central nervous system infections. Edited by Christopher C. Kibbler, Richard Barton, Neil A. R. Gow, Susan Howell, Donna M. MacCallum, and Rohini J. Manuel. Oxford University Press, 2017. http://dx.doi.org/10.1093/med/9780198755388.003.0022.

Full text

Abstract:

Infections of the central nervous system (CNS) are amongst the most severe of all fungal infections. Cryptococcus neoformans is the commonest cause of adult meningitis in many countries with high HIV prevalence. C gattii is usually seen in the tropics in apparently immunocompetent patients. Meningitis is also caused by Candida in premature babies, and by the dimorphic fungi in endemic areas. CNS infections with Aspergillus, the mucormycetes, and less common moulds usually present as intracranial mass lesions in immunocompromised hosts. Early suspicion, prompt imaging, and appropriate samples for culture, histology, and antigen and molecular tests are all critical for early diagnosis. Organism-specific antifungal therapy relies largely on liposomal amphotericin B and voriconazole, with therapeutic drug monitoring for the latter. Amphotericin B plus flucytosine is recommended for cryptococcal meningitis. Management of underlying conditions is also critical. Targeted prophylaxis in highest risk groups and pre-emptive therapy for HIV-associated cryptococcosis hold promise for prevention and improved outcome.

APA, Harvard, Vancouver, ISO, and other styles

18

Kosmidis, Chris, David W. Denning, and Eavan G. Muldoon. Fungal disease in cystic fibrosis and chronic respiratory disorders. Edited by Christopher C. Kibbler, Richard Barton, Neil A. R. Gow, Susan Howell, Donna M. MacCallum, and Rohini J. Manuel. Oxford University Press, 2017. http://dx.doi.org/10.1093/med/9780198755388.003.0037.

Full text

Abstract:

A range of fungal disease syndromes affect patients with chronic respiratory diseases and cystic fibrosis (CF). Invasive aspergillosis is increasingly recognized in seriously ill patients with chronic obstructive pulmonary disease, especially after high-dose steroids. Chronic pulmonary aspergillosis affects patients with pre-existing cavities or bullae, such as those with previous tuberculosis or atypical mycobacterial disease, bullous emphysema, sarcoidosis, pneumothorax, or treated lung cancer. In addition, fungi have become one of the most important trigger agents for asthma, and allergic bronchopulmonary aspergillosis may complicate up to 3.5% of cases of asthma and up to 15% of cases of CF, starting in childhood. CF patients are commonly colonized with fungal organisms, although the impact of such colonization on outcome is not clear. Aspergillus is the most common mould isolated from CF patients. Distinguishing between colonization and infection remains challenging. Candida is thought to be of no clinical significance; however, it has been associated with decline in lung function.

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!